The private equity consortium that will take over Hargreaves Lansdown has added a raft of new lenders to the group financing ...

Semaglutide was linked to a significantly lower risk of overdose than other antidiabetic drugs in patients with type 2 ...

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sartorius (0NIR – Research Report), with a price ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The CVC-led private equity consortium set to take over Hargreaves Lansdown has added a host of lenders to the group financing ...

On Tuesday, U.S. Senator Mike Braun (R-Ind.) questioned Novo Nordisk CEO Lars Fruergaard Jørgensen at the Senate Health, ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

Sen. Bernie Sanders (I-Vt.) noted that Novo Nordisk’s weight loss drug Ozempic sells for $969 a month in the U.S. but for ...